Michael Sayer/LinkedIn
Jun 6, 2025, 04:07
Michael Sayer: Incidence and predictors of ICI treatment–related cognitive impairment in a racial and ethnic diverse population
Michael Sayer, Postdoctoral Researcher at UCI School of Pharmacy and Pharmaceutical Sciences, shared a post on LinkedIn:
“This is the latest from research team, highlighting cognitive toxicities in patients receiving immune checkpoint inhibitor (ICI) therapies. In a longitudinal, prospective study, we collected patient-reported outcomes and found significant cognitive decline over time in patients receiving ICI therapy. We further identified that concurrent neuropsychiatric symptom burden- such as anxiety, fatigue, and depression- played a major role in exacerbating cognitive deficits.
To date, there have been limited studies characterizing cognitive toxicities associated with immunotherapy. Our work contributes to the emerging body of evidence highlighting this important issue. I’m grateful to contribute to this important research here at UCI and thankful for the support of my collaborators in this effort.”
Title: Incidence and predictors of immune checkpoint inhibitor treatment–related cognitive impairment in a racial and ethnic diverse population
Authors: Michael Sayer, Parisa Agrawal, Ding Quan Ng, Dalia Kagramanov, Julia Trudeau, Shivashankar Othy, Munjal M. Acharya & Alexandre Chan
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 6, 2025, 03:41
Jun 6, 2025, 01:10